May Health Welcomes New CEO to Lead PCOS Treatment Advancements
Portfolio - People | Mar 12, 2025 | Sofinnova Partners
May Health, a clinical-stage medical device company focused on treating Polycystic Ovary Syndrome (PCOS), announced the appointment of Colby Holtshouse as its new President and CEO. The company is developing a novel Ovarian Rebalancing technology, an ultrasound-guided, transvaginal procedure designed to restore ovulation in women resistant to oral medications. This technology is undergoing the REBALANCE clinical trial to obtain support for marketing authorization to address PCOS-related infertility. Colby's appointment, with her extensive industry experience, comes as May Health is poised to complete its study and move towards commercialization. The company's mission is fueled by substantial funding rounds led by Sofinnova Partners, Trill Impact, and BPI France.
Sectors
- Medical Devices
- Venture Capital
- Healthcare
Geography
- France – May Health is headquartered in Paris and has received investment from BPI France, indicating significant activity in France.
- United States – The clinical trials for May Health's PCOS treatment are taking place in the U.S., where the company also has a team based in California.
Industry
- Medical Devices – May Health is a clinical-stage medical device company developing novel treatments for PCOS.
- Venture Capital – Sofinnova Partners, Trill Impact, and BPI France are involved as investors in May Health, showcasing the role of venture capital in funding innovative healthcare solutions.
- Healthcare – The article focuses on May Health's efforts in developing a treatment for PCOS, a significant health challenge affecting many women.
Financials
- $25M – The amount raised by May Health in its Series B funding round to support its clinical activities.
- $10M – The initial Series A funding secured by May Health, led by Sofinnova Partners.
- €1.3 billion – The assets under management by Trill Impact, a co-investor in May Health.
- €4 billion – The assets under management by Sofinnova Partners, indicating their investment capacity in life sciences.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| May Health | Target Company | Company | A clinical-stage medical device company focused on developing treatments for PCOS-related infertility. |
| Colby Holtshouse | New President and CEO | Person | Recently appointed President and CEO of May Health, bringing extensive experience in women's health. |
| Sofinnova Partners | Lead Investor | Company | A leading European venture capital firm specializing in healthcare, backing May Health's innovations. |
| Trill Impact | Co-Investor | Company | An investment firm focused on impact private investments, co-investing in May Health’s latest funding round. |
| BPI France | Co-Investor | Company | The French national investment bank, co-investing in May Health as part of its equity investment strategy. |